Kelun-Biotech's pipeline and sales advance, but bribery probe clouds the story
Lung-cancer combo succeeds in Phase III The sac-TMT plus pembrolizumab combo met its main goal in first-line PD-L1-negative non-squamous lung cancer — the first ADC-plus-immunotherapy Phase III win in this group. Success lifts hopes for a big new use of its flagship drug, supporting the stock.
A major clinical win for the core drug is a key force behind the shares.
New dual-payload ADC enters clinic China's drug regulator cleared SKB565, the company's first dual-payload ADC, for human testing in advanced solid tumors. It is early-stage, but shows the pipeline keeps producing new candidates, which supports long-term growth expectations.
Pipeline progress is a core driver of biotech valuation.
Bribery allegations create legal and reputational risk A whistleblower letter alleges commercial bribery tied to the company's flagship drug sac-TMT, naming hospitals in Beijing. Kelun-Biotech denies it and threatens legal action. If proven, fines or sales restrictions could hurt; even unproven, it dents trust.
This is the main counterweight and a real risk to the stock.
Interim sales jump 112%, cash raised First-half product sales rose 112% to RMB 657 million, helped by insurance coverage for three sac-TMT uses and a new breast-cancer approval. The company also raised HK$2.72 billion in a share placing and dropped its 'B' marker, easing funding worries.
Strong commercial execution and fresh capital directly support the shares.
Partner's asthma drug moves to Phase III Partner Windward Bio reported positive Phase 2 asthma results for SKB378/WIN378, showing lasting lung-function gains with twice-yearly dosing, and started Phase 3. Success could bring milestone payments and royalties, adding a new growth path beyond cancer.
Partner validation of another pipeline asset is a fresh positive catalyst.